Results from an industry-funded study of cardiac resynchronization therapy defibrillators, medical implants that slow heart deterioration, found benefits more pronounced than in a preliminary analysis in June. But some cardiologists remain skeptical that the findings justify broad use of the $30,000 devices for patients with mild heart failure.
Trending:
Heart devices reduce hospitalization, study says